Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
Sunday, October 18, 2009 - 12:49
in Biology & Nature
La Jolla, CA -- October 18, 2009 -- Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D.